Onco-Innovations Targets Australian Tax Breaks to Propel Cancer Drug Trial

Canadian biotech Onco-Innovations creates Australian subsidiary to access 43.5% R&D tax rebates, funding Phase I trials for its nanoparticle cancer drug ONC010 amid a steep stock decline.

Onco-Innovations is betting on a new Australian subsidiary to unlock crucial financial incentives for its upcoming clinical work. The Canadian biotech firm announced the establishment of Onco-Innovations AU Pty. Ltd. this Tuesday, a move designed to qualify for the country's lucrative research and development tax rebate scheme. This strategic shift comes as the company's stock languishes near a yearly low, having shed nearly 58% of its value since January.

The financial appeal of the Australian move is clear. The local structure is a prerequisite to access a government program that offers cash rebates of up to 43.5% on qualified research expenditures. For a capital-intensive field like oncology, such a subsidy represents a significant financial lever. The new wholly-owned subsidiary will be supported by an agreement with advisors from RDI Partners, formally known as Research & Development Incentives Partners.

This operational setup in Australia complements an existing collaboration with the contract research organization Avance Clinical, which is slated to manage the actual conduct of the Phase I trials. The clinical focus will be on the company's lead candidate, ONC010, a novel inhibitor for cancer treatment based on nanoparticle technology.

To fund its ambitious plans, Onco-Innovations recently bolstered its balance sheet. In March, the company closed a private placement, raising approximately 1.22 million Canadian dollars. These fresh proceeds are earmarked for operations, research, and the final preparations for the clinical phase.

Simultaneously, management is investing in its market profile. A digital marketing campaign, budgeted at 213,000 euros, has been commissioned with the agency MCS and is scheduled to run until the end of July 2026. Notably, this initiative is being financed from funds that MCS had previously repaid to the company from an older contract.

Despite these strategic and financial preparations, investor sentiment remains deeply negative. The shares closed at 0.36 euros, hovering just above their 52-week low. The company now faces the critical task of transitioning from administrative groundwork to active clinical testing. With the marketing campaign funded until mid-2026, the clock is ticking for Onco-Innovations to demonstrate tangible progress with its lead asset and reverse its severe stock market decline.